Eli Lilly drug slows Alzheimer’s disease, study finds

Eli Lilly & Co.’s shares climbed in premarket trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly Alzheimer’s drug fails to prevent disease in trial
For subscribers